Guillain Barre Syndrome outbreak in Pune causes one death, 73 affected
HQ Team January 26, 2025: Over 73 people are down with Guillain Barre Syndrome (GBS), a rare nerve disorder, in Pune city in.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team January 26, 2025: Over 73 people are down with Guillain Barre Syndrome (GBS), a rare nerve disorder, in Pune city in.
HQ Team January 24, 2025: A recent study led by Empa researchers has developed a new mathematical model that improves predictions of how.
HQ Team January 24, 2025: A comprehensive genome-wide association study (GWAS) has found 298 regions containing DNA variations for increased risk of bipolar.
Hyundai ADM Bio, a subsidiary of South Korea’s Hyundai Bioscience, unveiled an oral cancer drug that allows patients to make a shift from intravenous.
HQ Team January 22, 2025: The Panna Tiger Reserve in Central India has revived its tiger population from the brink of extinction to.
China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic.
The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may.
US adults with attention deficit hyperactivity disorder (ADHD) rose from 10.6% to 15.2% between 2020 and 2023, and Covid-19 pandemic may be a.
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.